Notable Advances Volasertib Phase 2 Program

2/22/24 8:05:00 AM ET

$NTBL

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NTBL alert in real time by email

Predictive Precision Medicine Platform (PPMP) utilized to enrich program for clinically responding patients and reduce the risk, time, and cost of drug development
Volasertib Phase 2 trial initiation in relapsed/refractory acute myeloid leukemia anticipated in Q2 2024, and first data in Q4 2024
- Relapsed/refractory acute myeloid leukemia constitutes an urgent unmet medical need with typical treatment response rates of 15 percent and a median survival of 6 months or less

Get the next $NTBL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NTBL

Date	Price Target	Rating	Analyst
9/20/2024		Mkt Outperform → Mkt Perform	JMP Securities

More analyst ratings

Notable Labs to Present Data on September 4th at SOHO 2024
Society of Hematologic Oncology (SOHO) session to highlight volasertib program Phase 2 volasertib AML program expected to begin in the coming months FOSTER CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that the Company will present an overview of the Phase 2 program and additional data from preclinical studies evaluating volasertib for acute myeloid leukemia (AML) at the twelfth annual meeting of the Society for Hematologic Oncology (SOHO 2024), b
8/29/24 7:30:00 AM ET
$NTBL
Biotechnology: Pharmaceutical Preparations
Health Care
Notable Labs Announces CEO Transition
Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that Thomas A. Bock, MD has resigned from his positions as Chief Executive Officer (CEO) and member of the Board of Directors of the Company, effective today. Joseph Wagner, PhD, the Company's Chief Scientific Officer (CSO), has been appointed as interim CEO. T
8/26/24 4:05:00 PM ET
$NTBL
Biotechnology: Pharmaceutical Preparations
Health Care
Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study
FOSTER CITY, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of "Clearance to Proceed" from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming mo
7/24/24 7:30:00 AM ET
$NTBL
Biotechnology: Pharmaceutical Preparations
Health Care

Notable Advances Volasertib Phase 2 Program

Chat with this insight

Recent Analyst Ratings for
$NTBL

$NTBL
Leadership Updates

Live Leadership Updates

Notable Labs Announces CEO Transition

$NTBL
SEC Filings

Notable Labs Ltd. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Notable Labs Ltd. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update

Notable Labs Ltd. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

$NTBL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Notable Labs downgraded by JMP Securities

$NTBL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Zagger Kaile A. claimed no ownership of stock in the company (SEC Form 3)

Patsi Tuomo was granted 65,247 units of Ordinary Shares (SEC Form 4)

SEC Form 4 filed by Wagner Joseph P

$NTBL
Market Insights

Live Market Insights

Notable Labs shares are trading lower. The company announced progress for its Phase 2 volasertib program.

Notable Labs Announced Progress For The Phase 2 Volasertib Program Following Receipt Of "clearance To Proceed" From The FDA And Agreement On The Dosing Plan For Its Phase 2 Clinical Trial

Chardan Capital Maintains Buy on Notable Labs, Lowers Price Target to $5

$NTBL
Press Releases

Fastest customizable press release news feed in the world

Notable Labs to Present Data on September 4th at SOHO 2024

Notable Labs Announces CEO Transition

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

$NTBL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Notable Labs Ltd.

Notable Advances Volasertib Phase 2 Program

Chat with this insight

Recent Analyst Ratings for $NTBL

$NTBL Leadership Updates

Live Leadership Updates

Notable Labs Announces CEO Transition

$NTBL SEC Filings

Notable Labs Ltd. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Notable Labs Ltd. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update

Notable Labs Ltd. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

$NTBL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Notable Labs downgraded by JMP Securities

$NTBL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Zagger Kaile A. claimed no ownership of stock in the company (SEC Form 3)

Patsi Tuomo was granted 65,247 units of Ordinary Shares (SEC Form 4)

SEC Form 4 filed by Wagner Joseph P

$NTBL Market Insights

Live Market Insights

Notable Labs shares are trading lower. The company announced progress for its Phase 2 volasertib program.

Notable Labs Announced Progress For The Phase 2 Volasertib Program Following Receipt Of "clearance To Proceed" From The FDA And Agreement On The Dosing Plan For Its Phase 2 Clinical Trial

Chardan Capital Maintains Buy on Notable Labs, Lowers Price Target to $5

$NTBL Press Releases

Fastest customizable press release news feed in the world

Notable Labs to Present Data on September 4th at SOHO 2024

Notable Labs Announces CEO Transition

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

$NTBL Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Notable Labs Ltd.

Recent Analyst Ratings for
$NTBL

$NTBL
Leadership Updates

$NTBL
SEC Filings

$NTBL
Analyst Ratings

$NTBL
Insider Trading

$NTBL
Market Insights

$NTBL
Press Releases

$NTBL
Large Ownership Changes